Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GlaxoSmithKline has linked with Archemix to develop aptamer therapeutics, or synthesized oligonucleotides, against seven targets related to inflammatory diseases. GSK is taking a $6.5 million stake in Archemix, which recently announced a merger with fellow Boston-area biotech firm NitroMed. Archemix also gains an additional $21 million upfront and could receive up to $200 million in milestone payments for each of the seven aptamer targets covered in the deal. The biotech firm will be tasked with developing the aptamer therapeutics through clinical proof-of-mechanism.
This article has been sent to the following recipient: